Prokidney Corp. (PROK) Stock Price & Analysis
Prokidney Corp. (PROK) fell 2.34% to USD 1.67 as of June 10, 2026 at 07:19 UTC, according to Nexqual real-time market data.
PROK last closed at USD 1.71; the session ranged USD 1.63–1.77 on volume of 464,765 shares. Market capitalization is $504.44M, with a 52-week range of USD 0.54–7.13 (NCM). Source: Nexqual, June 10, 2026 at 07:19 UTC.
Key Statistics (as of June 10, 2026 at 07:19 UTC)
| Price | USD 1.67 |
|---|---|
| Change | ▼ 2.34% (down) |
| Previous Close | USD 1.71 |
| Open | USD 1.71 |
| Day Range | USD 1.63 – 1.77 |
| 52-Week Range | USD 0.54 – 7.13 |
| Volume | 464,765 shares |
| Market Cap | $504.44M |
| Exchange | NCM |
Technical Analysis (PROK)
Nexqual's technical model rates PROK "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.03 (neutral) |
| vs SMA50 | Below (USD 1.84) |
| MACD | -0.02 (negative) |
Analyst Ratings (PROK)
Wall Street analysts rate PROK "Buy" based on 6 analysts, with a mean price target of USD 6.25 (range USD 1–12), per Nexqual as of June 10, 2026 at 07:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 6.25 |
| High Target | USD 12 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 4 / 2 / 1 |
Earnings (PROK)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.14 |
| Revenue Estimate | $149,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.14 vs est -0.14 ▼ miss |
| 2025-12-31 | USD -0.14 vs est -0.15 ▲ beat |
| 2025-09-30 | USD -0.12 vs est -0.14 ▲ beat |
| 2025-06-30 | USD -0.13 vs est -0.14 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Financials & Fundamentals (PROK)
| Total Revenue | $889,000 |
|---|---|
| Revenue Growth (YoY) | -1.70% |
| Gross Margin | +100.00% |
| Operating Margin | -19881.86% |
| Profit Margin | +0.00% |
| ROE | -49.37% |
| Debt / Equity | 1.44 |
| Current Ratio | 9.06 |
| Total Cash | $224.94M |
| Total Debt | $3.78M |
| Free Cash Flow | $-78.63M |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Financial Health Score (PROK)
Nexqual rates Prokidney Corp.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $225M cash vs $4M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$79M, burning cash |
| Efficiency | Critical — ROE -49%, ROA -30.1% |
Ownership (PROK)
| Insider Ownership | +47.64% |
|---|---|
| Institutional Ownership | +24.25% |
| Shares Outstanding | 205.20M |
| Float | 156.93M |
| Short % of Float | +11.89% |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
Leadership (PROK)
Prokidney Corp. is led by Bruce Culleton (age 56), CEO & Director, per Nexqual as of June 10, 2026 at 07:19 UTC.
| CEO & Director | Bruce Culleton (age 56) |
|---|---|
| Chief Financial Officer | James Coulston (age 48) |
Major Backers & Investors (PROK)
Notable institutional backers of Prokidney Corp. include Suvretta Capital Management, LLC, Morgan Stanley, Millennium Management, according to Nexqual as of June 10, 2026 at 07:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 6.01% |
| Morgan Stanley | 5.53% |
| Millennium Management | 1.11% |
| Bleichroeder LP | 0.97% |
| Artia Global Partners LP | 0.88% |
| Hennion & Walsh Asset Management, Inc. | 0.79% |
| Renaissance Technologies | 0.61% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.12% |
| BlackRock | 0.68% |
| Geode Capital | 0.6% |
Source: Nexqual, June 10, 2026 at 07:19 UTC.
From Prokidney Corp.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.
- The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
- It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BGLC | BioNexus Gene Lab Corp | USD 2.18 | ▼ 1.14% |
| VOR | Vor Biopharma Inc. | USD 13.28 | ▲ 0.91% |
| CLDI | Calidi Biotherapeutics, Inc. | USD 0.18 | ▲ 3.55% |
| GRML | Greenland Mines Ltd | USD 0.3 | ▼ 2.61% |
| ABVEF | Above Food Ingredients Inc. | USD 0.12 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:19 UTC. This page is informational and not investment advice.